MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b — MIRACLE  

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Clinical Trial

Official title: MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: a Multicenter, Placebo-controlled, Double-blind Randomized Trial

Status Completed

Clinical Trial Summary

This is a placebo-controlled clinical trial to assess the efficacy and safety of a combination of lopinavir/ritonavir and Interferon beta-1b in hospitalized patients with MERS.

Clinical Trial Description

The aim of this study is to investigate the efficacy and safety of lopinavir /ritonavir and recombinant Interferon beta-1b combination given with optimal supportive care compared to placebo with optimal supportive care for patients with laboratory-confirmed MERS-CoV infection requiring hospital admission. ;

Related Conditions & MeSH terms

• Coronavirus Infections
• Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

• NCT number: NCT02845843
• Study type: Interventional
• Source: King Abdullah International Medical Research Center
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: July 2016
• Completion date: May 2020